HIGHLIGHTS
- who: Elena Vehns and collaborators from the Biomedical Engineering, Technical University of Munich (TUM), Garching, Germany have published the Article: Impact of MnTBAP and Baricitinib Treatment on Hutchinson-Gilford Progeria Fibroblasts, in the Journal: Pharmaceuticals 2022, 945 of /2022/
- what: The authors focus on a drug combination consisting of the superoxide dismutase mimetic and JAK1/2 inhibitor baricitinib (Bar) to restore phenotypic alterations in HGPS Treating HGPS with the MnTBAP/Bar combination improved mitochondrial functions and sustained Bar's positive effects on reducing progerin and pro-inflammatory factor levels. The authors investigated the effect of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.